DIM (Diindolylmethane)

What is DIM?

DIM (3,3'-diindolylmethane) is a phytonutrient that your body creates from indole-3-carbinol (I3C), a compound found in cruciferous vegetables — broccoli, cauliflower, kale, cabbage, Brussels sprouts. In the acidic environment of the stomach, I3C converts spontaneously to DIM and related condensation products.

Because dietary intake of cruciferous vegetables alone usually does not deliver therapeutic concentrations of DIM, supplemental forms (typically microencapsulated for bioavailability) have been studied in women's health.

How DIM works

DIM's primary effect is on the pathway of estrogen metabolism, not the amount of estrogen produced. The liver metabolizes estradiol along several pathways:

• 2-hydroxyestrone (2-OH) — weakly active, associated with lower breast cancer risk
• 4-hydroxyestrone (4-OH) — potentially genotoxic, associated with higher risk
• 16-alpha-hydroxyestrone (16-OH) — more proliferative, associated with estrogen-dominant symptoms

DIM upregulates CYP1A1, the enzyme that drives metabolism toward the 2-OH pathway. The net effect is a shift in the 2-OH:16-OH ratio — a biomarker that has been associated in observational studies with lower risk of estrogen-driven conditions.

DIM is not an aromatase inhibitor and does not lower estradiol levels directly.

What the evidence shows

The human evidence base for DIM is real but smaller than for many ingredients in this library, with most rigorous trials in breast cancer prevention and treatment-adjuvant contexts.

• A 2015 randomized double-blind trial in Breast Cancer Research & Treatment found 150 mg/day of DIM significantly increased the 2-OH:16-OH ratio in women with a history of early-stage breast cancer taking tamoxifen [1].
• A 2014 trial in Anticancer Research showed DIM supplementation in postmenopausal women with a history of breast cancer modulated estrogen metabolites favorably over 12 months [2].
• A 2017 systematic review in Cancer Causes & Control concluded that DIM and I3C consistently shift estrogen metabolism in the predicted direction across human trials, with safety profiles supporting longer-term use [3].

Evidence level: moderate — consistent biomarker shifts, with clinical-outcome evidence still maturing.

DIM for menopause and women over 40

The relevance to menopause is twofold. First, perimenopause is characterized by unopposed estrogen relative to progesterone, which often produces the symptoms women associate with estrogen dominance — breast tenderness, cyclical bloating, heavier periods, mood symptoms. DIM does not lower estrogen, but by shifting it toward less proliferative metabolites, it can reduce the downstream effects.

Second, women using HRT — particularly transdermal estradiol — sometimes want a metabolic complement that biases estrogen handling toward the more favorable pathway without reducing estrogen itself. DIM is one of the few non-prescription tools that does this.

For women with a personal or family history of estrogen-receptor-positive breast cancer, DIM should only be used under physician guidance — the data are favorable but not yet definitive enough for unsupervised use.

Dosage used in research

The dose used in most positive trials is 100–200 mg/day of bioavailable (microencapsulated) DIM. Effects on estrogen metabolites are detectable within 4–8 weeks. Discuss dosing with your provider, especially if you have a history of estrogen-receptor-positive cancer or are on tamoxifen, aromatase inhibitors, or any cytochrome-P450-cleared medication.

Safety and interactions

DIM is generally well tolerated. The most common side effects are GI discomfort and a temporary change in urine color (orange-yellow, harmless). DIM is a CYP enzyme modulator; significant drug interactions are possible with medications metabolized through CYP1A2 and CYP3A4. It should not be used in pregnancy or breastfeeding without supervision.

Where you will find it at kindr

DIM is the active in our Menopause Relief Patch formulation and is a recommendation in the menopause supplements guide for women with estrogen-dominant symptom patterns. For prescription evaluation of HRT, see our HRT guide.

Medically reviewed by Dr. Ana Lisa Carr, MD, MBA
Board-Certified Family Medicine Physician · Lead Provider / Medical Reviewer
NPI 1689841744 · Last reviewed: May 10, 2026